Dasatinib dose management for the treatment of chronic myeloid leukemia-Reference-Cited by-同舟云学术

Dasatinib dose management for the treatment of chronic myeloid leukemia

Published:2018-01-25 Issue:8 Volume:124 Page:1660-1672
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Talpaz Moshe¹^ORCID,Saglio Giuseppe²,Atallah Ehab³,Rousselot Philippe⁴

Affiliation:

1. Division of Hematology/Oncology, Department of Internal Medicine; University of Michigan Cancer Center; Ann Arbor Michigan

2. Department of Clinical and Biological Sciences; University of Turin, San Luigi Hospital; Orbassano-Torino Italy

3. Department of Hematology and Oncology; Medical College of Wisconsin; Milwaukee Wisconsin

4. Department of Hematology and Oncology, Versailles Medical Center, INSERM UMR 1173; University of Versailles Saint-Quenti-en-Yvelines; Paris Saclay Le Chesnay France

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference56 articles.

1. Overriding imatinib resistance with a novel ABL kinase inhibitor;Shah;Science.,2004

2. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias;Talpaz;N Engl J Med.,2006

3. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol.,2016

4. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol.,2015

5. SEER Stat Fact Sheets: Chronic myeloid leukemia (CML) Statistics at a Glance https://seer.cancer.gov/statfacts/html/cmyl.html 2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Development of a novel copper metabolism-related risk model to predict prognosis and tumor microenvironment of patients with stomach adenocarcinoma;Frontiers in Pharmacology;2023-05-22

3. Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs;ESMO Open;2023-02

4. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib;Cancer Immunology, Immunotherapy;2023-01-05

5. Treatment of Cancer Gene Changes in Chronic Myeloid Leukemia by Big Data Analysis Platform-Based Dasatinib;Applied Bionics and Biomechanics;2022-06-10